Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ligelizumab in Allergic Asthma Extension
NCT02075008Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of ligelizumab in allergic asthma, sponsored by Novartis. Started Mar 2014; status: terminated.
02
Drugs
ligelizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT02075008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075008.